Between 1995 and 2014, a majority of new drugs and medicines approved by the US Food and Drug Administration (FDA) recouped the average cost of drug development through net discounted sales within a ...
FDA commissioner Scott Gottlieb on Monday explained to attendees of RAPS’ Regulatory Convergence conference some steps FDA is taking to make the clinical end of drug development more efficient and ...
Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...
The FDA has proposed new policies to speed up the development and lower the cost of biosimilar agents for cancer and other serious illnesses. These policies include “major updates to simplify ...
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced new draft guidance aimed at reducing the cost and complexity of developing biosimilar medicines, a move the agency says could help ...
Researchers at Kent have established a computational protocol that could accelerate the development of more effective ...
Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is among the must-buy penny stocks to invest in now. Recursion Pharmaceuticals ...
Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results